UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice.
UA-30, a novel compound with a favorable pharmacokinetic and safety profile, is reported that delayed systemic aging in naturally aged mice, as indicated by reduced frailty, slowed epigenetic age, extended lifespan, and improved muscle function.